CRIS Current Research Information System

DERENZINI, ENRICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.880
AS - Asia 2.764
EU - Europa 2.643
AF - Africa 160
SA - Sud America 137
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 2
Totale 9.593
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.837
SG - Singapore 804
VN - Vietnam 783
GB - Regno Unito 686
CN - Cina 682
SE - Svezia 484
DE - Germania 348
IT - Italia 282
HK - Hong Kong 221
IN - India 160
RU - Federazione Russa 144
FR - Francia 110
IE - Irlanda 100
BR - Brasile 92
UA - Ucraina 91
NL - Olanda 82
CH - Svizzera 79
ZA - Sudafrica 63
EE - Estonia 61
FI - Finlandia 48
TG - Togo 47
JP - Giappone 31
CA - Canada 29
BG - Bulgaria 25
CI - Costa d'Avorio 24
PL - Polonia 23
HR - Croazia 19
NG - Nigeria 17
BE - Belgio 16
AR - Argentina 15
IR - Iran 13
KR - Corea 13
BD - Bangladesh 10
JO - Giordania 10
CL - Cile 9
ES - Italia 9
ID - Indonesia 9
MX - Messico 9
GR - Grecia 8
AT - Austria 7
EC - Ecuador 7
LB - Libano 7
LT - Lituania 6
SC - Seychelles 6
CZ - Repubblica Ceca 5
PE - Perù 4
VE - Venezuela 4
AU - Australia 3
MY - Malesia 3
NZ - Nuova Zelanda 3
TR - Turchia 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
CO - Colombia 2
DZ - Algeria 2
HU - Ungheria 2
IS - Islanda 2
KZ - Kazakistan 2
PH - Filippine 2
PY - Paraguay 2
RO - Romania 2
RS - Serbia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AZ - Azerbaigian 1
BO - Bolivia 1
BY - Bielorussia 1
DM - Dominica 1
DO - Repubblica Dominicana 1
EG - Egitto 1
EU - Europa 1
GT - Guatemala 1
HT - Haiti 1
IQ - Iraq 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
NC - Nuova Caledonia 1
NO - Norvegia 1
PK - Pakistan 1
TM - Turkmenistan 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 9.593
Salva come PNG Salva come JPEG
Città #
Southend 605
Singapore 507
Fairfield 448
Ashburn 411
Chandler 344
Dong Ket 310
Woodbridge 228
Houston 222
Hong Kong 215
Wilmington 203
Seattle 191
Ann Arbor 173
Santa Clara 163
Princeton 141
Cambridge 133
Beijing 121
Dublin 100
Boardman 97
Ho Chi Minh City 92
Hanoi 77
Bern 76
Nanjing 72
Westminster 63
Padova 60
Los Angeles 52
Lomé 47
New York 47
Jacksonville 45
Berlin 42
Bologna 42
Helsinki 42
Jinan 40
Dallas 35
Hefei 35
Changsha 34
San Diego 32
Florence 28
Saint Petersburg 27
Shenyang 27
Buffalo 26
Hebei 26
Tokyo 26
Bremen 25
Sofia 25
Abidjan 24
Hyderabad 22
Redondo Beach 22
Turin 21
Milan 20
Frankfurt am Main 19
Redwood City 19
Toronto 19
Jiaxing 17
Medford 17
Munich 17
Warsaw 17
Abeokuta 16
Brussels 15
Dearborn 15
Ningbo 15
Norwalk 15
São Paulo 14
London 13
Mülheim 13
Nanchang 13
Phoenix 13
Redmond 13
Zhengzhou 13
Chicago 12
Guangzhou 12
Seoul 12
Taizhou 12
Hangzhou 11
Amman 10
Falkenstein 10
Haiphong 10
Shanghai 10
Haikou 9
San Francisco 9
Falls Church 8
Ha Long 8
Mountain View 8
Olalla 8
Quận Bình Thạnh 8
Taiyuan 8
Biên Hòa 7
Lanzhou 7
Tianjin 7
Yubileyny 7
Da Nang 6
Düsseldorf 6
Jakarta 6
Monmouth Junction 6
Pune 6
Rijeka 6
Rio de Janeiro 6
Vũng Tàu 6
Andover 5
Brooklyn 5
Bühl 5
Totale 6.413
Salva come PNG Salva come JPEG
Nome #
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 244
A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. 236
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases. 228
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 226
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 216
A phase 2 trial of fludarabine and mitoxantrone chemoterapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma 212
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience 196
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. 195
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 187
An isolated penile mass in a young adult turned out to be a primary marginal zone lymphoma of the penis. A case report and a review of literature. 185
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. 184
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. 183
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 182
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 182
Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue 181
RALE051: a novel established cell line of sporadic Burkitt lymphoma 179
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma 174
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 173
The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 173
Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation in Follicular Lymphoma. 171
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 171
Treatment of colorectal cancer liver metastases 169
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 169
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience 169
Inhibition of DNA repair by the small molecule Chk1/Chk2 inhibitor PF-0477736 (Pfizer) in B-acute lymphoblastic leukemia (ALL) 164
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 160
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia 156
Extramedullary myeloid tumour of the stomach and duodenum presenting without acute myeloblastic leukemia: a diagnostic and therapeutic challenge. 155
Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series. 150
The synergistic efficacy of Chk1/Chk2 inhibitors and doxorubicin in the treatment of acute lymphoblastic leukemia 149
Bendamustine: role and evidence in lymphoma therapy, an overview. 148
Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. 147
Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. 146
In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL) 146
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. 145
Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. 144
Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin. 141
Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports. 141
Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia. 140
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma). 140
Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. 139
Impact of adjuvant chemotherapy on time to relapse in cholangiocarcinoma. 138
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma. Leuk Lymphoma. 133
The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia 130
Clinical safety and efficacy of adjuvant chemotherapy in radically resected cholangiocarcinoma patients. 129
Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. 127
Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. 123
The Small Molecule CHK1/CHK2 Inhibitor PF-0477736 (Pfizer) Demonstrates Single Agent Activity and Synergizes with Chemotherapy in Diffuse Large B-Cell Lymphoma 122
Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma. 120
Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties. 118
FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study. 117
Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients. 117
Identification of Novel Potential Predisposing Variants in Familial Acute Myeloid Leukemia 116
GEMOX AS FIRST-LINE CHEMOTHERAPY IN ADVANCED PANCREATIC CANCER (APC): A MONOISTITUTIONAL EXPERIENCE. 110
Systemic adjuvant chemotherapy after resection of colorectal cancer metastases 110
SINGLE-AGENT INHIBITION OF CHECKPOINT KINASE 1 (CHK1) AND 2 (CHK2) BY PF-0477736 (PFIZER) AS A NEW PROMISING THERAPY IN B-ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 105
Postchemotherapy PET evaluation correlates with patient outcome in paediatric Hodgkin's disease. 104
IMPACT OF MULTIDISCIPLINARY APPROACH ON SURVIVAL OF PATIENTS WITH KLATSKIN TUMOR 103
The small molecule CHK1/CHK2 inhibitor PF-0477736 (Pfizer) demonstrates single agent activity in diffuse large B-cell lymphoma 97
The tratment of liver metastases from colorectal cancer: questions more than answers? 96
METRONOMIC CAPECITABINE IN ADVANCED PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): PRELIMINARY RESULTS. 81
Phase I/II trial of continuous hepatic arterial infusion (HAI) of Irinotecan in patients with hepatocellular carcinoma (HCC). Preliminary results 80
Liver metastases from colorectal cancer 75
null 75
Phase I/II trial of continuous hepatic arterial infusion (HAI) of irinotecan in patients with hepatocellular carcinoma (HCC). 66
Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma 62
Totale 9.750
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.663
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.663
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021764 0 0 0 0 0 66 7 45 93 34 52 467
2021/20221.385 196 53 104 144 108 71 45 71 48 89 245 211
2022/20231.492 197 200 83 189 96 120 29 81 198 48 115 136
2023/2024360 28 62 14 45 22 91 19 14 9 28 6 22
2024/20251.370 43 211 109 93 252 43 119 39 14 132 35 280
2025/20261.528 307 246 251 174 360 190 0 0 0 0 0 0
Totale 9.750